The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors

In metastatic triple-negative breast cancer (TNBC), the efficacy of immune checkpoint inhibitors (ICIs) in combination with chemotherapy has been demonstrated in randomized clinical trials (RCTs). Despite this, an indirect comparison is not yet available. Reconstruction of individual patient data fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Spazio, Lorenzo, Rivano, Melania, Cancanelli, Luca, Chiumente, Marco, Mengato, Daniele, Messori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743568/
https://www.ncbi.nlm.nih.gov/pubmed/35028245
http://dx.doi.org/10.7759/cureus.21065
_version_ 1784629931657920512
author Di Spazio, Lorenzo
Rivano, Melania
Cancanelli, Luca
Chiumente, Marco
Mengato, Daniele
Messori, Andrea
author_facet Di Spazio, Lorenzo
Rivano, Melania
Cancanelli, Luca
Chiumente, Marco
Mengato, Daniele
Messori, Andrea
author_sort Di Spazio, Lorenzo
collection PubMed
description In metastatic triple-negative breast cancer (TNBC), the efficacy of immune checkpoint inhibitors (ICIs) in combination with chemotherapy has been demonstrated in randomized clinical trials (RCTs). Despite this, an indirect comparison is not yet available. Reconstruction of individual patient data from Kaplan-Meier curves allows the indirect comparison of different treatments. We analyzed six overall survival (OS) curves from three RCTs. In patients with ≥1% positivity, atezolizumab was found to determine a significantly better OS than pembrolizumab. As regards pembrolizumab, adopting a threshold of PD-L1 positivity ≥10% (as opposed to ≥1%) improved median survival to a remarkable extent (23.0 vs 15.5 months).
format Online
Article
Text
id pubmed-8743568
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-87435682022-01-12 The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors Di Spazio, Lorenzo Rivano, Melania Cancanelli, Luca Chiumente, Marco Mengato, Daniele Messori, Andrea Cureus Oncology In metastatic triple-negative breast cancer (TNBC), the efficacy of immune checkpoint inhibitors (ICIs) in combination with chemotherapy has been demonstrated in randomized clinical trials (RCTs). Despite this, an indirect comparison is not yet available. Reconstruction of individual patient data from Kaplan-Meier curves allows the indirect comparison of different treatments. We analyzed six overall survival (OS) curves from three RCTs. In patients with ≥1% positivity, atezolizumab was found to determine a significantly better OS than pembrolizumab. As regards pembrolizumab, adopting a threshold of PD-L1 positivity ≥10% (as opposed to ≥1%) improved median survival to a remarkable extent (23.0 vs 15.5 months). Cureus 2022-01-09 /pmc/articles/PMC8743568/ /pubmed/35028245 http://dx.doi.org/10.7759/cureus.21065 Text en Copyright © 2022, Di Spazio et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Di Spazio, Lorenzo
Rivano, Melania
Cancanelli, Luca
Chiumente, Marco
Mengato, Daniele
Messori, Andrea
The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title_full The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title_fullStr The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title_full_unstemmed The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title_short The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
title_sort degree of programmed death-ligand 1 (pd-l1) positivity as a determinant of outcomes in metastatic triple-negative breast cancer treated with first-line immune checkpoint inhibitors
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743568/
https://www.ncbi.nlm.nih.gov/pubmed/35028245
http://dx.doi.org/10.7759/cureus.21065
work_keys_str_mv AT dispaziolorenzo thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT rivanomelania thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT cancanelliluca thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT chiumentemarco thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT mengatodaniele thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT messoriandrea thedegreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT dispaziolorenzo degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT rivanomelania degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT cancanelliluca degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT chiumentemarco degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT mengatodaniele degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors
AT messoriandrea degreeofprogrammeddeathligand1pdl1positivityasadeterminantofoutcomesinmetastatictriplenegativebreastcancertreatedwithfirstlineimmunecheckpointinhibitors

Ejemplares similares